A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Save

Date Added
June 21st, 2019
PRO Number
Pro00090038
Researcher
Antonio Giordano

List of Studies

Silhouette
Keywords
Cancer/Breast
Summary

This study is for patients with HER2-positive breast cancer that has metastasized. The study is being done to see if the patient's breast cancer can be stabilized and the time that the patient lives with this breast cancer can be lengthened by adding a new drug to the usual combination of drugs.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2?) Breast Cancer (KEYNOTE-756) Save

Date Added
May 30th, 2019
PRO Number
Pro00086999
Researcher
Antonio Giordano

List of Studies

Silhouette
Keywords
Cancer/Breast, Men's Health, Women's Health
Summary

The purpose of the study is to test the safety and effectiveness of the study drug, pembrolizumab (MK-3475) with certain types of chemotherapy and endocrine therapy, as well as, to see how well the subject's body handles the study drug.
If subject's meet the criteria, they will be assigned to 1 of 2 groups by chance, similar to flipping a coin, in order to decide which study treatment they will receive. Group A will receive the study drug, pembrolizumab, with certain types of chemotherapy and endocrine therapy. Group B will receive placebo, with certain types of chemotherapy and endocrine therapy. Pembrolizumab or placebo will be given by vein about once every 3 weeks.
This is a long-term study, if subject's agree to participate, they will be in the study for approximately 12 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

INCREASING SOCIOECONOMICALLY DISADVANTAGED PATIENTS' ENGAGEMENT IN BREAST CANCER SURGERY DECISIONMAKING THROUGH A SHARED DECISION MAKING INTERVENTION Save

Date Added
April 10th, 2019
PRO Number
Pro00087587
Researcher
Andrea Abbott

List of Studies

Silhouette
Keywords
Cancer/Breast
Summary

This study is for breast cancer patients who are making decisions about breast cancer surgery. This study is being done to learn about how patients and their surgeons make decisions about breast cancer surgery.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

PHASE III PLACEBO-CONTROLLED TRIAL TO EVALUATE DEXAMETHASONE USE FOR EVEROLIMUS INDUCED ORAL STOMATITIS: PREVENTION VERSUS EARLY TREATMENT APPROACHES Save

Date Added
March 19th, 2019
PRO Number
Pro00087480
Researcher
Antonio Giordano

List of Studies

Silhouette
Keywords
Cancer/Breast
Summary

This study is for subjects who have been diagnosed with cancer and will be receiving a drug called everolimus as part of your usual care. The purpose of this study is to see if treating patients with dexamethasone mouthwash at the start of cancer treatment will lower the chance of getting painful mouth sores.

Institution
MUSC
Recruitment Contact
Nancy McGaha
(864) 725-5105
nmcgaha@selfregional.org

A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer Save

Date Added
March 4th, 2019
PRO Number
Pro00086652
Researcher
Frank Brescia

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Breast
Summary

This study is for patients who are 70 years old or over and have been recently diagnosed with estrogen receptor positive, HER2 negative metastatic breast cancer. The purpose of this study is to find out the side effects that the standard, FDA-approved combination treatment of letrozole or fulvestrant and palbociclib has on patients 70 years old and over.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer Save

Date Added
January 22nd, 2019
PRO Number
Pro00084301
Researcher
Antonio Giordano

List of Studies

Silhouette
Keywords
Cancer/Breast, Drug Studies, Women's Health
Summary

This is an open-label, nonrandomized, dose escalation and dose expansion, safety, efficacy, PK and PD evaluation study of SAR439859 administered orally as monotherapy, then in combination with palbociclib. The study will last approximately 26 months, and participation in the study may last 4 to 8 weeks or longer. The length of participation in this study will depend on how well subjects tolerate the study drug and the condition of their disease.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Stress Reactivity among African American Breast Cancer Survivors Save

Date Added
October 19th, 2018
PRO Number
Pro00060958
Researcher
Chanita Hughes-halbert

List of Studies


Profiles_link
Keywords
Cancer/Breast, Inflammation, Minorities
Summary

Outcomes following a breast cancer diagnosis are different by race and ethnicity with African American women having poorer survival compared to Caucasian women. Research has shown that differences in personal health factors can contribute to breast cancer outcomes and explain racial differences. This study will examine how personal-level factors relating to biological, psychological, and physiological issues play a role in outcomes among African American breast cancer survivors.

Institution
MUSC
Recruitment Contact
Melanie Jefferson
843-876-2430
sweatma@musc.edu

Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502 Save

Date Added
October 18th, 2018
PRO Number
Pro00082693
Researcher
Frank Brescia

List of Studies


Profiles_link
Keywords
Cancer/Breast
Summary

This study is for patients with breast cancer who have enrolled or are planning to enroll to the Alliance study A011502, "Aspirin for Breast Cancer Study" (or ABC study).

Institution
MUSC
Recruitment Contact
Nancy McGaha
(864) 725-5105
nmcgaha@selfregional.org

PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION Save

Date Added
March 20th, 2018
PRO Number
Pro00076282
Researcher
Jennifer Harper

List of Studies


Profiles_link
Keywords
Cancer/Breast
Summary

This study is for patients who have been diagnosed with stage 2 or stage 3 breast cancer and their doctor has recommended that they receive radiation therapy after mastectomy to prevent your breast cancer from coming back. The purpose of this study is to determine whether a short-course radiation therapy option (3 to 4 weeks) after mastectomy is as safe and effective in the setting of breast reconstruction as the usual 5 to 6 week treatment course.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

PROSPECTIVE EVALUATION OF CARVEDILOL IN PREVENTION OF CARDIAC TOXICITY IN PATIENTS WITH METASTATIC HER-2+ BREAST CANCER, PHASE III Save

Date Added
March 1st, 2018
PRO Number
Pro00073765
Researcher
Frank Brescia

List of Studies


Profiles_link
Keywords
Cancer/Breast
Summary

This study is for patients with metastatic breast cancer who are receiving therapy that may cause heart problems. The purpose of this study is to test whether carvedilol can reduce the occurrence of heart problems during their cancer treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login